Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Recommendation of “Buy” from Analysts

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) has been given a consensus rating of “Buy” by the twenty-four ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, six have given a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $271.43.

A number of research analysts have issued reports on the stock. Piper Sandler upped their target price on shares of Vertex Pharmaceuticals from $245.00 to $249.00 and gave the company a “neutral” rating in a research report on Thursday, April 21st. Royal Bank of Canada downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $269.00 price target on the stock. in a research report on Thursday, February 3rd. Wells Fargo & Company increased their price target on shares of Vertex Pharmaceuticals from $270.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, April 5th. JPMorgan Chase & Co. increased their price target on shares of Vertex Pharmaceuticals from $260.00 to $288.00 and gave the company an “overweight” rating in a research report on Thursday, January 27th. Finally, Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $279.00 price target on the stock. in a research report on Monday, April 4th.

In other news, EVP Ourania Tatsis sold 325 shares of the firm’s stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $230.95, for a total transaction of $75,058.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Bastiano Sanna sold 1,040 shares of the firm’s stock in a transaction that occurred on Wednesday, February 2nd. The stock was sold at an average price of $250.98, for a total transaction of $261,019.20. The disclosure for this sale can be found here. Insiders have sold a total of 47,950 shares of company stock valued at $12,975,167 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in VRTX. Camden National Bank grew its stake in shares of Vertex Pharmaceuticals by 73.0% in the fourth quarter. Camden National Bank now owns 27,395 shares of the pharmaceutical company’s stock valued at $6,474,000 after buying an additional 11,561 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of Vertex Pharmaceuticals by 19.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 24,613 shares of the pharmaceutical company’s stock valued at $4,465,000 after buying an additional 4,047 shares in the last quarter. Lincoln National Corp grew its stake in shares of Vertex Pharmaceuticals by 24.0% in the third quarter. Lincoln National Corp now owns 1,271 shares of the pharmaceutical company’s stock valued at $231,000 after buying an additional 246 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Vertex Pharmaceuticals by 5.1% in the third quarter. PNC Financial Services Group Inc. now owns 31,140 shares of the pharmaceutical company’s stock valued at $5,649,000 after buying an additional 1,524 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its stake in shares of Vertex Pharmaceuticals by 25.1% in the third quarter. Thompson Siegel & Walmsley LLC now owns 45,101 shares of the pharmaceutical company’s stock valued at $8,181,000 after buying an additional 9,039 shares in the last quarter. 90.30% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals stock opened at $273.22 on Monday. The company has a current ratio of 4.46, a quick ratio of 4.30 and a debt-to-equity ratio of 0.05. Vertex Pharmaceuticals has a 1 year low of $176.36 and a 1 year high of $292.75. The company has a market cap of $69.82 billion, a PE ratio of 30.26, a PEG ratio of 1.83 and a beta of 0.62. The company’s 50-day moving average is $257.38 and its two-hundred day moving average is $227.13.

About Vertex Pharmaceuticals (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Featured Stories